Patient characteristics of the DLBCL cohorts
| . | HCs (N = 60) . | CR after DLBCL (N = 70) . | ND DLBCL (N = 67) . | R/R DLBCL (N = 32) . | P value∗ . |
|---|---|---|---|---|---|
| Sex, n (%) | .25 | ||||
| Male | 30 (50) | 40 (57) | 39 (58) | 23 (72) | |
| Female | 30 (50) | 30 (43) | 28 (42) | 9 (28) | |
| Median age (95% CI), y | 65.4 (51.2-94.2) | 70.8 (21.0-88.7) | 70.1 (23.0-90.5) | 72.1 (34.6-85.4) | .43 |
| Disease type, n (%) | .43 | ||||
| DLBCL | 62 (89) | 59 (88) | 25 (78) | ||
| tFL | 7 (10) | 7 (10) | 5 (16) | ||
| tMZL | 1 (1) | 1 (2) | 2 (6) | ||
| Cell of origin, n (%) | .73 | ||||
| GCB | 31 (58) | 31 (60) | 11 (50) | ||
| Non-GCB | 22 (42) | 21 (40) | 11 (50) | ||
| No data | 17 | 15 | 10 | ||
| Genetic risk stratifiers, n (%) | .60 | ||||
| No/single expressor | 22 (43) | 23 (47) | 8 (38) | ||
| Double expressor | 21 (41) | 19 (39) | 11 (52) | ||
| Triple expressor | 7 (14) | 3 (6) | 1 (5) | ||
| Double hit | 1 (2) | 4 (8) | 1 (5) | ||
| Triple hit | 0 | 0 | 0 | ||
| No data | 19 | 18 | 11 | ||
| R-IPI, n (%) | .40 | ||||
| Low (0-2) | 32 (46) | 24 (41) | 9 (31) | ||
| High (3-5) | 38 (54) | 35 (59) | 20 (69) | ||
| No data | 0 | 8 | 3 | ||
| IPI factors n (%) | |||||
| Stage ≥III | 54 (77) | 41 (61) | 25 (78) | .38 | |
| LDH >ULN | 46 (66) | 42 (63) | 23 (72) | .17 | |
| Age >60 years | 50 (71) | 54 (81) | 26 (81) | .30 | |
| ECOG PS ≥2 | 8 (11) | 7 (10) | 8 (25) | .04 | |
| Extranodal sites ≥2 | 30 (43) | 30 (45) | 7 (22) | .18 | |
| B-symptoms | 16 (23) | 8 (12) | 9 (28) | .11 | |
| Tumor bulk | 12 (17) | 7 (10) | 4 (13) | .60 |
| . | HCs (N = 60) . | CR after DLBCL (N = 70) . | ND DLBCL (N = 67) . | R/R DLBCL (N = 32) . | P value∗ . |
|---|---|---|---|---|---|
| Sex, n (%) | .25 | ||||
| Male | 30 (50) | 40 (57) | 39 (58) | 23 (72) | |
| Female | 30 (50) | 30 (43) | 28 (42) | 9 (28) | |
| Median age (95% CI), y | 65.4 (51.2-94.2) | 70.8 (21.0-88.7) | 70.1 (23.0-90.5) | 72.1 (34.6-85.4) | .43 |
| Disease type, n (%) | .43 | ||||
| DLBCL | 62 (89) | 59 (88) | 25 (78) | ||
| tFL | 7 (10) | 7 (10) | 5 (16) | ||
| tMZL | 1 (1) | 1 (2) | 2 (6) | ||
| Cell of origin, n (%) | .73 | ||||
| GCB | 31 (58) | 31 (60) | 11 (50) | ||
| Non-GCB | 22 (42) | 21 (40) | 11 (50) | ||
| No data | 17 | 15 | 10 | ||
| Genetic risk stratifiers, n (%) | .60 | ||||
| No/single expressor | 22 (43) | 23 (47) | 8 (38) | ||
| Double expressor | 21 (41) | 19 (39) | 11 (52) | ||
| Triple expressor | 7 (14) | 3 (6) | 1 (5) | ||
| Double hit | 1 (2) | 4 (8) | 1 (5) | ||
| Triple hit | 0 | 0 | 0 | ||
| No data | 19 | 18 | 11 | ||
| R-IPI, n (%) | .40 | ||||
| Low (0-2) | 32 (46) | 24 (41) | 9 (31) | ||
| High (3-5) | 38 (54) | 35 (59) | 20 (69) | ||
| No data | 0 | 8 | 3 | ||
| IPI factors n (%) | |||||
| Stage ≥III | 54 (77) | 41 (61) | 25 (78) | .38 | |
| LDH >ULN | 46 (66) | 42 (63) | 23 (72) | .17 | |
| Age >60 years | 50 (71) | 54 (81) | 26 (81) | .30 | |
| ECOG PS ≥2 | 8 (11) | 7 (10) | 8 (25) | .04 | |
| Extranodal sites ≥2 | 30 (43) | 30 (45) | 7 (22) | .18 | |
| B-symptoms | 16 (23) | 8 (12) | 9 (28) | .11 | |
| Tumor bulk | 12 (17) | 7 (10) | 4 (13) | .60 |
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B cell; LDH, lactate dehydrogenase; tFL, transformed FL; tMZL, transformed marginal zone lymphoma; ULN, upper limit of normal.
P value by the χ2 test or the Fisher exact test for nominal and categorial variables. The analysis of variance was used for metric variables. Boldface P values are statistically significant.